Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Disc Medicine and keeping the price target at $118.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Douglas Tsao has given his Buy rating due to a combination of factors related to bitopertin’s regulatory and clinical outlook. He argues that pursuing a traditional approval route for erythropoietic protoporphyria should lower regulatory risk, noting that both trial data and feedback from physicians and patients point to a meaningful improvement in real-world functioning and quality of life.
Tsao also emphasizes that the planned APOLLO Phase 3 trial is specifically structured to address prior concerns, including placebo effects, through a longer treatment period and more rigorous co‑primary endpoints. With enrollment targeted for completion in 2026 and an FDA decision anticipated by mid‑2027, he believes the study design and mechanistic rationale together make eventual approval of bitopertin likely, supporting a positive stance on Disc Medicine’s shares.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year.